Eukaryote
IRA round 2 begins as drugmakers sign on to price negotiation process with CMS
Myasthenic Syndromes, Congenital, Mediation, Prices, Medicare, Ira (eukaryote), drugmakers
Nimbus Therapeutics Announces Leadership Transition: Abbas Kazimi Appointed as New CEO
Nimbus Therapeutics, CEO transition, Abbas Kazimi, Jeb Keiper, biotechnology, computational drug discovery
BridgeBio Oncology Therapeutics Goes Public via $450M SPAC Merger
BridgeBio, oncology, SPAC merger, Helix Acquisition Corp. II, KRAS inhibitors, cancer pipeline, RAS pathway, PI3K pathway
Key Takeaways from #JPM25: Strategic Partnerships and Acquisitions Dominate the JP Morgan Healthcare Conference
JP Morgan Healthcare Conference, #JPM25, biopharma industry, acquisitions, partnerships, Eli Lilly, Zealand Pharma, GSK, Scorpion Therapeutics